Gaudium IVF and Women Health Limited, incorporated in 2015, operates in the IVF and fertility treatment segment in India . The company provides services such as IVF, IUI, ICSI, egg freezing, laser-assisted embryo implantation, infertility surgeries and surrogacy-related fertility treatments . It follows a hub-and-spoke model with 7 hubs and 28 spokes across India . Revenue from operations was ₹7,072.40 lakhs in FY25 .

The Company is led by Promoter, i.e.,DR. MANIKA KHANNA, DR. PEEYUSH KHANNA AND VISHAD KHANNA

The Revenues from operations for the Period ended on Sep 30 2025, and Fiscals ended on Mar 31, 2025, 2024 and 2023 were ₹ 4,974.97 Lakh, ₹ 7,095.84 Lakh, ₹ 4,815.31 Lakh, and ₹ 4,426.02 Lakh, The EBITDA for the Period ended on Sep 30 2025, and Fiscals ended on Mar 31, 2025, 2024 and 2023 were ₹ 1,895.23 Lakh, ₹ 2,862.59 Lakh, ₹ 1,927.47 Lakh, and ₹ 2,006.55 Lakh, The Profit after Tax for the Period ended on Sep 30 2025, and Fiscals ended on Mar 31, 2025, 2024 and 2023 were were ₹ 1,250.56 Lakh, ₹ 1,912.74 Lakh, ₹ 1,031.69 Lakh, and ₹ 1,352.54 Lakh, respectively. This indicates a steady growth in financial performance.

The Company Key Performance Indicates the pre-issue EPS of ₹ 3.12 and post-issue EPS of ₹ 2.63 for FY25. The pre-issue P/E ratio is 25.32x,while the post-issue P/E ratio is 30.06x against the Industry P/E ratio is 26.49x The company's ROE for FY25 is 41.31% and RoNW is 41.71%The Annualised EPS is ₹ 3.44x and P/E is ₹ 22.99x,  These metrics suggest that the IPO is Fully priced.

 
The Grey Market Premium (GMP) of Gaudium IVF showing listing gains of 0%.Given the company's financial performance and the valuation of the IPO, we recommend  Investors to Avoid to the Gaudium IVF Limited, IPO for Listing gain or Long Term Purposes.